System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Yoshio Yamaoka is an expert in Gastroenterology at Baylor College of Medicine (United States). Yoshio Yamaoka has authored 1,172 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 3,656 (community average: 125). How the SLR is computed.

LeadR Profile

Yoshio Yamaoka Baylor College of Medicine United States
3 656 ScienceLeadR Reputation 3656

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Infectiology - Hepatology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1987 - 2026
Source: PubMed

Baylor College of Medicine

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1172

Citations

Citations: 49 588 1st author: 82 Last author: 510 Unique author: 41

Main journals

Gastroenterology 67
Transplant Proc 43
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature 39
Helicobacter 36
Transplantation 36

Best Journals

Nature 2
Science 2
Ann Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Helicobacter pylori eradication and gastric cancer prevention: current evidence and future perspectives.
PMID 42803410 — helicobacter pylori, helicobacter, neoplasms, mucous membrane, stomach neoplasms		Expert Rev Gastroenterol Hepatol20260
Genomic Insights and Antimicrobial Resistance Profiling of Diarrheagenic Escherichia coli in Bhutan: A Retrospective Whole-Genome Sequencing Study.
PMID 42514046 — escherichia, epidemiology, whole genome sequencing, genome, escherichia coli, diarrhea, virulence		Microorganisms20261
CagA-dependent expression of anti-inflammatory cytokine IL-13 and TNFRSF member Fn14 in Helicobacter pylori infected gastric cells and tissues.
PMID 42382345 — gastritis, atrophic, cytokines, cells, interleukin-13, helicobacter pylori, helicobacter, gastritis, tissues, infections		Front Microbiol20260
Low-Abundance and Fragmentary Helicobacter pylori DNA Detected in Phenotypically Negative Gastric Biopsies Using Targeted Sequencing.
PMID 42352236 — helicobacter pylori, helicobacter, biopsy, dna		Biomolecules20260
A Cross-Sectional Dual-Site Analysis of the Gastric Antral and Duodenal Mucosa-Associated Microbiome Across Gastroesophageal Reflux Disease Phenotypes.
PMID 42351647 — genes, genes, rrna, pyloric antrum, phenotype, duodenum, mucous membrane, gastroesophageal reflux, microbiota		Biomedicines20260

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 1
Phase 4 1

By status:

Completed 1
Recruiting 1

By type:

Interventional 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
14 day PCAB based High dose Dual Therapy and14 day PCAB based Triple Therapy vs 14 day PPI based Reverse Hybrid Therapy
NCT05191888 — helicobacter pylori, metronidazole, urea, clarithromycin, amoxicillin, helicobacter, therapeutics, rabeprazole		Phase 4Recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS